Gene ther­a­py start­up Lo­can­abio lays off staff, nar­rows fo­cus on Duchenne

Biotech start­up Lo­can­abio has laid off 30% of its work­force, por­tend­ing a lim­it­ed scope go­ing for­ward for the gene ther­a­py de­vel­op­er, backed with more than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER